Compare GSK plc (GSK) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Workiva Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Workiva Inc trades at $68.14 (market cap $3.76B). The key difference: GSK plc is far larger — about 27.3× Workiva Inc's market cap, and GSK plc pays a 3.57% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| GSK | WK | |
|---|---|---|
Market Cap | $102.60B | $3.76B |
Sector | Health | Technology |
52-Week High | $61.18 | $93.31 |
52-Week Low | $38.22 | $44.31 |
Enterprise Value | $123.04B | $3.73B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Workiva (WK) trades at $68.07, up 1.11% today, with strong technical momentum and bullish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 revenue of $255 million exceeding guidance. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $69 consensus target. The stock shows robust revenue growth but elevated valuation multiples with a P/E of 82.2.
Outlook remains constructive given consistent earnings outperformance and strong subscription growth, though high valuation and negative net income in 2025 present risks. The company's AI platform expansion and Fortune 500 customer base support long-term growth potential, but investors should monitor profitability improvement and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
